A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B
Sponsor: Merck Sharp & Dohme LLC
A PHASE1/PHASE2 clinical study on Esophageal Squamous Cell Carcinoma, this trial is actively recruiting participants. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 41 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
41 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 36 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adana, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Bangkok, Thailand , Beijing, China , Berlin, Germany , Chuo-ku, Japan , Chur, Switzerland , Dresden, Germany , Düsseldorf, Germany , East Syracuse, United States and 36 more locations